{"title": "Investigaci\u00f3n del cemento \u00f3seo con o sin el ablandador de cemento Inossia\u2122 para las fracturas vertebrales por compresi\u00f3n (SOFTBONE)", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT05676320", "hostname": "ichgcp.net", "description": "El prop\u00f3sito general de realizar este estudio es evaluar la seguridad y eficacia de V-Flex y V-Steady para el aumento de fracturas por compresi\u00f3n vertebral oste.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2022-12-14", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Investigaci\u00f3n del cemento \u00f3seo con o sin el ablandador de cemento Inossia\u2122 para las fracturas vertebrales por compresi\u00f3n (SOFTBONE)\n[Inossia AB](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Inossia%20AB)\nUn ECA multic\u00e9ntrico, simple ciego, para documentar la seguridad y la eficacia del uso de un cemento \u00f3seo con o sin el ablandador de cemento Inossia\u2122 para pacientes con fracturas vertebrales por compresi\u00f3n\nDescripci\u00f3n general del estudio\nEstado\nCondiciones\nIntervenci\u00f3n / Tratamiento\nDescripci\u00f3n detallada\nLa investigaci\u00f3n cl\u00ednica es un estudio prospectivo, simple ciego, controlado y multic\u00e9ntrico de fracturas vertebrales por compresi\u00f3n tratadas mediante vertebroplastia o cifoplastia con PMMA solo (V-Steady) o PMMA mezclado con Inossia\u2122 Cement Softener (V-Flex).\nEl prop\u00f3sito general de realizar este estudio es confirmar la seguridad y eficacia del ablandador de cemento Inossia\u2122 mezclado con PMMA para el aumento de las fracturas por compresi\u00f3n vertebral osteopor\u00f3tica y verificar que el V-Flex es, al menos, comparable (no inferior) al Productos de PMMA utilizados en la actualidad.\nTodos los pacientes elegibles ser\u00e1n invitados a participar en el estudio. Se inscribir\u00e1 un total de 150 pacientes en el estudio.\nTipo de estudio\nInscripci\u00f3n (Anticipado)\nFase\n- No aplica\nContactos y Ubicaciones\nEstudio Contacto\n- Nombre: Malin K Nilsson, PhD\n- N\u00famero de tel\u00e9fono: +46702688674\n- Correo electr\u00f3nico:\n[malin.nilsson@inossia.com](mailto:malin.nilsson@inossia.com?subject=NCT05676320, SOFTBONE 1512:1, Investigating Bone Cement With or Without Inossia\u2122 Cement Softener for Vertebral Compression Fractures)\nCopia de seguridad de contactos de estudio\n- Nombre: Anna Gibernau\n- N\u00famero de tel\u00e9fono: +34 936 690 575\n- Correo electr\u00f3nico:\n[anna.gibernau@clementine.globa](mailto:anna.gibernau@clementine.globa?subject=NCT05676320, SOFTBONE 1512:1, Investigating Bone Cement With or Without Inossia\u2122 Cement Softener for Vertebral Compression Fractures)\nUbicaciones de estudio\n-\nAlemania\n-\n-\nMannheim, Alemania\n- Reclutamiento\n- Mannheim University Hospital\n-\nContacto:\n- Gregor Reisig\n-\nInvestigador principal:\n- David Eschmann\n-\nMechernich, Alemania\n- Reclutamiento\n- Hospital in Mechernich\n-\nInvestigador principal:\n- Robert Pfugmacher\n-\n-\n-\nCanad\u00e1\n-\nAlberta\n-\nCalgary, Alberta, Canad\u00e1\n- A\u00fan no reclutando\n- Beam Radiology\n-\nContacto:\n- Olivier Clerk-Lamalice\n-\nInvestigador principal:\n- Olivier Clerk-Lamalice\n-\n-\n-\nEspa\u00f1a\n-\n-\nMadrid, Espa\u00f1a\n- Reclutamiento\n- Cl\u00ednico San Carlos\n-\nContacto:\n- Rafael Luque Perez\n-\nInvestigador principal:\n- Rafael Luque Perez\n-\nMadrid, Espa\u00f1a\n- Reclutamiento\n- Puerta de Hierro\n-\nContacto:\n- Raquel Gutierrez Gonzalez\n-\nInvestigador principal:\n- Raquel Gutierrez Gonzalez\n-\nValladolid, Espa\u00f1a\n- Reclutamiento\n- University Hospital in Valladolid\n-\nContacto:\n- David Noriega\n-\nInvestigador principal:\n- David Noriega\n-\n-\n-\nPolonia\n-\n-\n\u0141\u00f3d\u017a, Polonia\n- Reclutamiento\n- Lodz University Hospital\n-\nContacto:\n- Maciej Radek\n-\nContacto:\n- Jakub Janowski\n-\nInvestigador principal:\n- Maciej Radek\n-\nSub-Investigador:\n- Jakub Janowski\n-\n-\nCriterios de participaci\u00f3n\nCriterio de elegibilidad\nEdades elegibles para estudiar\nAcepta Voluntarios Saludables\nG\u00e9neros elegibles para el estudio\nDescripci\u00f3n\nCriterios de inclusi\u00f3n:\n- Consentimiento informado obtenido antes de cualquier actividad relacionada con el estudio (las actividades relacionadas con el estudio son cualquier procedimiento que no se habr\u00eda realizado durante el manejo normal del paciente, es decir, el est\u00e1ndar de atenci\u00f3n);\n- Fractura por compresi\u00f3n vertebral osteopor\u00f3tica sintom\u00e1tica sin tratamiento m\u00e9dico previo o que no haya respondido dentro de los 6 meses;\n- M\u00e1ximo de 1 nivel de fracturas vertebrales por compresi\u00f3n elegibles para tratamiento localizadas en el nivel Th5 a L5 y verificadas por resonancia magn\u00e9tica o gammagraf\u00eda \u00f3sea;\n- Reducci\u00f3n de la altura de la(s) v\u00e9rtebra(s) afectada(s) con una compresi\u00f3n de la pared anterior que no exceda el 60% en comparaci\u00f3n con el cuerpo vertebral normal m\u00e1s cercano determinado por rayos X;\n- Tiene dolor que se correlaciona con los niveles fracturados que requieren la ingesta regular de analg\u00e9sicos y/o causan una discapacidad sustancial de la vida diaria;\n- Puntuaci\u00f3n de dolor \u2265 40 mm medido por VAS que se correlaciona con al menos uno de los niveles de fractura (escala 0 - 100 mm) en la visita de selecci\u00f3n;\n- \u00cdndice de discapacidad de Oswestry > 20 (escala de 0 a 100);\n- \u00cdndice SF-12PCS < 80 (escala 0 - 100);\n- Paciente con capacidad comunicativa para comprender el procedimiento y participar en el estudio y cumplir con el programa de seguimiento.\nCriterio de exclusi\u00f3n:\n- Pacientes menores de 18 a\u00f1os;\n- Cualquier fractura por estallido;\n- Fracturas inestables definidas por d\u00e9ficit neurol\u00f3gico o ensanchamiento del proceso interespinoso seg\u00fan lo evaluado por el investigador, as\u00ed como cifosis > 30\u00b0, traslaci\u00f3n > 4 mm;\n- Malignidad establecida o sospechada de la v\u00e9rtebra fracturada. Hemangioma de la v\u00e9rtebra fracturada;\n- Trauma de alta energ\u00eda o diagn\u00f3stico cl\u00ednico de n\u00facleo pulposo herniado o estenosis espinal severa como lo sugiere la debilidad progresiva;\n- Tiene s\u00edntomas o d\u00e9ficits neurol\u00f3gicos, o radiculopat\u00eda relacionada con las v\u00e9rtebras fracturadas;\n- Pacientes con un IMC extremadamente alto, es decir, IMC \u2265 40;\n- Previamente tratado con vertebroplastia o cifoplastia;\n- Pacientes con enfermedades concomitantes que pueden empeorar con el tratamiento invasivo de la fractura, como p. disfunci\u00f3n cardiopulmonar grave (incluido el aneurisma a\u00f3rtico), a juicio del investigador\n- Coagulopat\u00eda irreversible o trastorno hemorr\u00e1gico. Nota sobre coagulopat\u00edas reversibles: pueden participar pacientes que toman Coumadin u otros anticoagulantes. Los investigadores deben seguir las pr\u00e1cticas de rutina para la interrupci\u00f3n perioperatoria y el reinicio de los anticoagulantes;\n- Infecci\u00f3n sist\u00e9mica activa o infecci\u00f3n cut\u00e1nea local en el sitio de punci\u00f3n;\n- Embarazo o lactancia;\n- Pacientes con dependencia qu\u00edmica o drogas conocidas o con antecedentes m\u00e9dicos de abuso de drogas;\n- Pacientes que est\u00e1n cumpliendo pena de prisi\u00f3n;\n- Haber participado en otro estudio de investigaci\u00f3n dentro de los 30 d\u00edas anteriores a la inclusi\u00f3n.\n- Marcapasos\n- Radioterapia previa o activa que afecta a la columna vertebral\nPlan de estudios\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: Tratamiento\n- Asignaci\u00f3n: Aleatorizado\n- Modelo Intervencionista: Asignaci\u00f3n paralela\n- Enmascaramiento: \u00danico\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nExperimental: Flexi\u00f3n en V\nCemento \u00f3seo, incluido el ablandador de cemento Inossia\n|\n|\nCemento \u00f3seo, incluido el ablandador de cemento Inossia. Tratamiento de la fractura por compresi\u00f3n vertebral\nOtros nombres:\n|\n|\nComparador activo: V-estable\nCemento \u00f3seo solo\n|\n|\nCemento \u00f3seo solo\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nNuevas fracturas\nPeriodo de tiempo: 1 a\u00f1o\n|\n|\nEvaluar la eficacia despu\u00e9s de la administraci\u00f3n del dispositivo en investigaci\u00f3n en comparaci\u00f3n con PMMA medida por el cambio de nuevas fracturas.\n|\n|\n1 a\u00f1o\n|\n|\nUbicaci\u00f3n de las fracturas\nPeriodo de tiempo: 1 a\u00f1o\n|\n|\nEval\u00fae la ubicaci\u00f3n de nuevas fracturas: adyacentes o no adyacentes a la v\u00e9rtebra tratada o refracturas de la v\u00e9rtebra tratada despu\u00e9s de la administraci\u00f3n del dispositivo en investigaci\u00f3n en comparaci\u00f3n con PMMA.\n|\n|\n1 a\u00f1o\n|\n|\nMomento de las fracturas\nPeriodo de tiempo: 1 a\u00f1o\n|\n|\nEval\u00fae el momento de las fracturas adyacentes, no adyacentes y refractarias de la v\u00e9rtebra tratada despu\u00e9s de la administraci\u00f3n del dispositivo en investigaci\u00f3n en comparaci\u00f3n con PMMA.\n|\n|\n1 a\u00f1o\nMedidas de resultado secundarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nDolor medido por EVA\nPeriodo de tiempo: 12 meses\n|\n|\nEvaluar el cambio en el dolor de espalda en puntos de tiempo 5 d\u00edas, 3 meses, 12 meses despu\u00e9s de la administraci\u00f3n del dispositivo en investigaci\u00f3n en comparaci\u00f3n con PMMA seg\u00fan lo medido por la Escala Anal\u00f3gica Visual (VAS): escala 0-100, donde 0 es sin dolor y 100 es el el peor dolor imaginable\n|\n|\n12 meses\n|\n|\nFunci\u00f3n por ODI\nPeriodo de tiempo: 12 meses\n|\n|\nEvaluar el cambio en la funci\u00f3n en puntos de tiempo 5 d\u00edas, 3 meses, 12 meses despu\u00e9s de la administraci\u00f3n del dispositivo en investigaci\u00f3n en comparaci\u00f3n con PMMA seg\u00fan lo medido por el \u00cdndice de discapacidad de Oswestry (ODI): escala 0-100% donde una puntuaci\u00f3n m\u00e1s alta significa un peor resultado\n|\n|\n12 meses\n|\n|\nCalidad de vida relacionada con la salud por SF-12\nPeriodo de tiempo: 12 meses\n|\n|\nEvaluar el cambio en la calidad de vida relacionada con la salud en puntos de tiempo 5 d\u00edas, 3 meses, 12 meses despu\u00e9s de la administraci\u00f3n del dispositivo en investigaci\u00f3n en comparaci\u00f3n con PMMA seg\u00fan lo medido por SF-12: escala 0-100 donde una puntuaci\u00f3n m\u00e1s alta significa un mejor resultado\n|\n|\n12 meses\n|\n|\nSeguridad medida por eventos adversos\nPeriodo de tiempo: 12 meses\n|\n|\nEval\u00faa la seguridad del ablandador de cemento Inossia\u2122 medida por eventos adversos\n|\n|\n12 meses\n|\n|\nCamas de hospital\nPeriodo de tiempo: 1 semana\n|\n|\nRegistre el n\u00famero de d\u00edas de cama de hospital (dentro del hospital, hogar de ancianos, etc.) durante la primera semana\n|\n|\n1 semana\n|\n|\nLa altura vertebral\nPeriodo de tiempo: 12 meses\n|\n|\nLa altura vertebral a los 12 meses en comparaci\u00f3n con la l\u00ednea de base por rayos X (altura promedio del cuerpo vertebral leve)\n|\n|\n12 meses\n|\n|\nUso de analg\u00e9sicos\nPeriodo de tiempo: 12 meses\n|\n|\nRegistrar el uso de analg\u00e9sicos y comparar con la escala analg\u00e9sica de la OMS\n|\n|\n12 meses\n|\n|\nLista de verificaci\u00f3n del r\u00e9gimen de tratamiento osteopor\u00f3tico\nPeriodo de tiempo: 12 meses\n|\n|\nRegistrar el r\u00e9gimen de tratamiento osteopor\u00f3tico\n|\n|\n12 meses\nColaboradores e Investigadores\nPatrocinador\nColaboradores\nInvestigadores\n- Investigador principal: David Noriega, University Hospital in Valladolid\nPublicaciones y enlaces \u00fatiles\nPublicaciones Generales\n-\n[Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33. doi: 10.1097/00005650-199603000-00003.](https://pubmed.ncbi.nlm.nih.gov/8628042)\n-\n[Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine (Phila Pa 1976). 2000 Nov 15;25(22):2940-52; discussion 2952. doi: 10.1097/00007632-200011150-00017.](https://pubmed.ncbi.nlm.nih.gov/11074683)\n-\n[Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992 Feb;7(2):221-7. doi: 10.1002/jbmr.5650070214.](https://pubmed.ncbi.nlm.nih.gov/1570766)\n-\n[Leidig G, Minne HW, Sauer P, Wuster C, Wuster J, Lojen M, Raue F, Ziegler R. A study of complaints and their relation to vertebral destruction in patients with osteoporosis. Bone Miner. 1990 Mar;8(3):217-29. doi: 10.1016/0169-6009(90)90107-q.](https://pubmed.ncbi.nlm.nih.gov/2322694)\n-\n[International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med. 1997 Jan 23;336(4):309-15. doi: 10.1056/NEJM199701233360422. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/8995096)\n- International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. 1-5-1996.\n- Code of Federal Regulations. Title 21, Volume 8. Part 812, Investigational Device Exemptions, Revised 2006.\n- World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification of Paragraph 29 by the WMA General Assembly, Washington 2002 and Note of Clarification on Paragraph 30 by the WMA General assembly, Tokyo 2004.\n-\n[de Bruin TW. Iodide-induced hyperthyroidism with computed tomography contrast fluids. Lancet. 1994 May 7;343(8906):1160-1. doi: 10.1016/s0140-6736(94)90265-8. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/7910248)\n-\n[ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med. 1999 Aug 15;18(15):1905-42. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/10532877)\n-\n[Lane JI, Maus TP, Wald JT, Thielen KR, Bobra S, Luetmer PH. Intravertebral clefts opacified during vertebroplasty: pathogenesis, technical implications, and prognostic significance. AJNR Am J Neuroradiol. 2002 Nov-Dec;23(10):1642-6.](https://ichgcp.net/es/clinical-trials-registry/publications/107278-intravertebral-clefts-opacified-during-vertebroplasty-pathogenesis-technical-implications-and)\n-\n[Trout AT, Kallmes DF, Gray LA, Goodnature BA, Everson SL, Comstock BA, Jarvik JG. Evaluation of vertebroplasty with a validated outcome measure: the Roland-Morris Disability Questionnaire. AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2652-7.](https://ichgcp.net/es/clinical-trials-registry/publications/107279-evaluation-of-vertebroplasty-with-a-validated-outcome-measure-the-roland-morris-disability)\n-\n[Trout AT, Gray LA, Kallmes DF. Vertebroplasty in the inpatient population. AJNR Am J Neuroradiol. 2005 Aug;26(7):1629-33.](https://ichgcp.net/es/clinical-trials-registry/publications/107280-vertebroplasty-in-the-inpatient-population)\n-\n[Layton KF, Thielen KR, Koch CA, Luetmer PH, Lane JI, Wald JT, Kallmes DF. Vertebroplasty, first 1000 levels of a single center: evaluation of the outcomes and complications. AJNR Am J Neuroradiol. 2007 Apr;28(4):683-9.](https://ichgcp.net/es/clinical-trials-registry/publications/107281-vertebroplasty-first-1000-levels-of-a-single-center-evaluation-of-the-outcomes-and-complications)\n-\n[Voormolen MH, van Rooij WJ, Sluzewski M, van der Graaf Y, Lampmann LE, Lohle PN, Juttmann JR. Pain response in the first trimester after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures with or without bone marrow edema. AJNR Am J Neuroradiol. 2006 Aug;27(7):1579-85.](https://ichgcp.net/es/clinical-trials-registry/publications/107282-pain-response-in-the-first-trimester-after-percutaneous-vertebroplasty-in-patients-with-osteoporotic)\n-\n[Palussiere J, Berge J, Gangi A, Cotten A, Pasco A, Bertagnoli R, Jaksche H, Carpeggiani P, Deramond H. Clinical results of an open prospective study of a bis-GMA composite in percutaneous vertebral augmentation. Eur Spine J. 2005 Dec;14(10):982-91. doi: 10.1007/s00586-003-0664-2. Epub 2005 Jun 2.](https://pubmed.ncbi.nlm.nih.gov/15931511)\n-\n[Cortet B, Cotten A, Boutry N, Flipo RM, Duquesnoy B, Chastanet P, Delcambre B. Percutaneous vertebroplasty in the treatment of osteoporotic vertebral compression fractures: an open prospective study. J Rheumatol. 1999 Oct;26(10):2222-8.](https://pubmed.ncbi.nlm.nih.gov/10529144)\n-\n[Prather H, Van Dillen L, Metzler JP, Riew KD, Gilula LA. Prospective measurement of function and pain in patients with non-neoplastic compression fractures treated with vertebroplasty. J Bone Joint Surg Am. 2006 Feb;88(2):334-41. doi: 10.2106/JBJS.D.02670.](https://ichgcp.net/es/clinical-trials-registry/publications/107283-prospective-measurement-of-function-and-pain-in-patients-with-non-neoplastic-compression-fractures)\n-\n[Vogl TJ, Proschek D, Schwarz W, Mack M, Hochmuth K. CT-guided percutaneous vertebroplasty in the therapy of vertebral compression fractures. Eur Radiol. 2006 Apr;16(4):797-803. doi: 10.1007/s00330-005-0021-4. Epub 2005 Dec 7.](https://pubmed.ncbi.nlm.nih.gov/16333624)\n-\n[Gaughen JR Jr, Jensen ME, Schweickert PA, Kaufmann TJ, Marx WF, Kallmes DF. Lack of preoperative spinous process tenderness does not affect clinical success of percutaneous vertebroplasty. J Vasc Interv Radiol. 2002 Nov;13(11):1135-8. doi: 10.1016/s1051-0443(07)61955-1.](https://pubmed.ncbi.nlm.nih.gov/12427813)\n-\n[Do HM, Kim BS, Marcellus ML, Curtis L, Marks MP. Prospective analysis of clinical outcomes after percutaneous vertebroplasty for painful osteoporotic vertebral body fractures. AJNR Am J Neuroradiol. 2005 Aug;26(7):1623-8.](https://ichgcp.net/es/clinical-trials-registry/publications/107284-prospective-analysis-of-clinical-outcomes-after-percutaneous-vertebroplasty-for-painful-osteoporotic)\n-\n[Voormolen MH, Mali WP, Lohle PN, Fransen H, Lampmann LE, van der Graaf Y, Juttmann JR, Jansssens X, Verhaar HJ. Percutaneous vertebroplasty compared with optimal pain medication treatment: short-term clinical outcome of patients with subacute or chronic painful osteoporotic vertebral compression fractures. The VERTOS study. AJNR Am J Neuroradiol. 2007 Mar;28(3):555-60.](https://ichgcp.net/es/clinical-trials-registry/publications/107285-percutaneous-vertebroplasty-compared-with-optimal-pain-medication-treatment-short-term-clinical)\n- Guidance Document for the Preparation of IDEs for Spinal Systems, January 13, 2000.\n- Clinical Trial Considerations:Vertebral Augmentation Devices to Treat Spinal lnsufficiency Fractures, October 24, 2004.\n- Clauss W. How big is the risk of an examination with x-ray contrast media of patients with known hypersensitivity to CM and for allergic patients? In Dawson P and Clauss W (eds.): Contrast media in practice, 2nd edition, Springer-Verlag, Berlin-Heidelberg, 1999:98-99.\n-\n[Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990 Jun;175(3):621-8. doi: 10.1148/radiology.175.3.2343107.](https://pubmed.ncbi.nlm.nih.gov/2343107)\n- Wijn D and Mullen V. Biocompatibility of Acrylic lmplants. In Biocompatibility of Clinical lmplant Materials. Edited,CRC Press, 1981.\n-\n[Trout AT, Kallmes DF, Kaufmann TJ. New fractures after vertebroplasty: adjacent fractures occur significantly sooner. AJNR Am J Neuroradiol. 2006 Jan;27(1):217-23.](https://ichgcp.net/es/clinical-trials-registry/publications/107286-new-fractures-after-vertebroplasty-adjacent-fractures-occur-significantly-sooner)\n-\n[Uppin AA, Hirsch JA, Centenera LV, Pfiefer BA, Pazianos AG, Choi IS. Occurrence of new vertebral body fracture after percutaneous vertebroplasty in patients with osteoporosis. Radiology. 2003 Jan;226(1):119-24. doi: 10.1148/radiol.2261011911.](https://pubmed.ncbi.nlm.nih.gov/12511679)\n-\n[Grados F, Depriester C, Cayrolle G, Hardy N, Deramond H, Fardellone P. Long-term observations of vertebral osteoporotic fractures treated by percutaneous vertebroplasty. Rheumatology (Oxford). 2000 Dec;39(12):1410-4. doi: 10.1093/rheumatology/39.12.1410.](https://pubmed.ncbi.nlm.nih.gov/11136886)\n-\n[Kim CW, Minocha J, Wahl CE, Garfin SR. Response of fractured osteoporotic bone to polymethylacrylate after vertebroplasty: case report. Spine J. 2004 Nov-Dec;4(6):709-12. doi: 10.1016/j.spinee.2004.05.002.](https://pubmed.ncbi.nlm.nih.gov/15597484)\n-\n[McKiernan F, Faciszewski T, Jensen R. Quality of life following vertebroplasty. J Bone Joint Surg Am. 2004 Dec;86(12):2600-6. doi: 10.2106/00004623-200412000-00003.](https://pubmed.ncbi.nlm.nih.gov/15590842)\n-\n[Gill JB, Kuper M, Chin PC, Zhang Y, Schutt R Jr. Comparing pain reduction following kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Pain Physician. 2007 Jul;10(4):583-90.](https://ichgcp.net/es/clinical-trials-registry/publications/107287-comparing-pain-reduction-following-kyphoplasty-and-vertebroplasty-for-osteoporotic-vertebral)\n-\n[Eck JC, Nachtigall D, Humphreys SC, Hodges SD. Comparison of vertebroplasty and balloon kyphoplasty for treatment of vertebral compression fractures: a meta-analysis of the literature. Spine J. 2008 May-Jun;8(3):488-97. doi: 10.1016/j.spinee.2007.04.004. Epub 2007 May 29.](https://pubmed.ncbi.nlm.nih.gov/17588820)\n-\n[Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999 Jun 14;159(11):1215-20. doi: 10.1001/archinte.159.11.1215.](https://pubmed.ncbi.nlm.nih.gov/10371229)\n-\n[Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ 3rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993 May 1;137(9):1001-5. doi: 10.1093/oxfordjournals.aje.a116756.](https://pubmed.ncbi.nlm.nih.gov/8317445)\n-\n[Silverman SL, Minshall ME, Shen W, Harper KD, Xie S; Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum. 2001 Nov;44(11):2611-9. doi: 10.1002/1529-0131(200111)44:113.0.co;2-n.](https://ichgcp.net/es/clinical-trials-registry/publications/107288-the-relationship-of-health-related-quality-of-life-to-prevalent-and-incident-vertebral-fractures-in)\n-\n[Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998 May 15;128(10):793-800. doi: 10.7326/0003-4819-128-10-199805150-00001.](https://pubmed.ncbi.nlm.nih.gov/9599190)\nFechas de registro del estudio\nFechas importantes del estudio\nInicio del estudio (Actual)\nFinalizaci\u00f3n primaria (Anticipado)\nFinalizaci\u00f3n del estudio (Anticipado)\nFechas de registro del estudio\nEnviado por primera vez\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\nPublicado por primera vez (Estimar)\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Estimar)\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n\u00daltima verificaci\u00f3n\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- SOFTBONE 1512:1\nPlan de datos de participantes individuales (IPD)\n\u00bfPlanea compartir datos de participantes individuales (IPD)?\nInformaci\u00f3n sobre medicamentos y dispositivos, documentos del estudio\nEstudia un producto farmac\u00e9utico regulado por la FDA de EE. UU.\nEstudia un producto de dispositivo regulado por la FDA de EE. UU.\nproducto fabricado y exportado desde los EE. UU.\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre Fractura por compresi\u00f3n vertebral\n-\nNCT05912504Reclutamiento\n[Seguimiento a largo plazo de fracturas vertebrales agudas por compresi\u00f3n en pacientes hospitalizados tratados con medicina alternativa y complementaria integrada: una revisi\u00f3n retrospectiva de gr\u00e1ficos y una encuesta](https://ichgcp.net/es/clinical-trials-registry/NCT05912504)Fractura por compresi\u00f3n vertebral | Compresi\u00f3n Vertebral | Medicina Tradicional Coreana | Medicina Integrativa Coreana\n-\nNCT05519332Reclutamiento\n[Plastia percut\u00e1nea de disco vertebral para fracturas por compresi\u00f3n vertebrales osteopor\u00f3ticas muy graves toracolumbares](https://ichgcp.net/es/clinical-trials-registry/NCT05519332)Fractura Osteopor\u00f3tica de V\u00e9rtebra\n-\nNCT05337696Reclutamiento\n[Reconstrucci\u00f3n vertebral circunferencial de fracturas por compresi\u00f3n osteopor\u00f3ticas utilizando un novedoso implante bipedicular Peek (RECONSTRUCT)](https://ichgcp.net/es/clinical-trials-registry/NCT05337696)Fracturas Vertebrales por Compresi\u00f3n | Fracturas vertebrales osteopor\u00f3ticas por compresi\u00f3n\n-\nNCT04835428Reclutamiento\n[STAND - Estudio del Kit AGN1 LOEP SV Comparado con PMMA en Pacientes con Fracturas Vertebrales por Compresi\u00f3n](https://ichgcp.net/es/clinical-trials-registry/NCT04835428)Fractura por compresi\u00f3n vertebral | Compresi\u00f3n Vertebral | Fractura de compresi\u00f3n\n-\nNCT04821739ReclutamientoFractura Vertebral | Fractura por compresi\u00f3n vertebral | Compresi\u00f3n Vertebral\n-\nNCT04795765ReclutamientoFracturas vertebrales osteopor\u00f3ticas por compresi\u00f3n\n-\nNCT04064710ReclutamientoFractura(s) por compresi\u00f3n del cuerpo vertebral\n-\nNCT02387905Reclutamiento\n[Aumento con cemento en la prevenci\u00f3n de la fractura por compresi\u00f3n del cuerpo vertebral despu\u00e9s de la radiocirug\u00eda estereot\u00e1ctica de la columna vertebral en pacientes con tumores s\u00f3lidos y met\u00e1stasis espinales](https://ichgcp.net/es/clinical-trials-registry/NCT02387905)Neoplasia s\u00f3lida maligna metast\u00e1sica | Neoplasia maligna metast\u00e1sica en la columna vertebral\n-\nNCT02285868ReclutamientoOsteoartritis | Osteoartritis de rodilla | S\u00edndrome del t\u00fanel carpiano | S\u00edndrome de pinzamiento del hombro | Esguince | Artrosis de cadera | Fractura | Artrosis de columna\n-\nNCT02657265TerminadoTrauma | Fracturas de columna | Lesiones de espalda | Fracturas Vertebrales por Compresi\u00f3n\nEnsayos cl\u00ednicos sobre Flexi\u00f3n en V\n-\nNCT03226418Activo, no reclutando\n[Integraci\u00f3n de la evaluaci\u00f3n geri\u00e1trica y el perfil gen\u00e9tico para personalizar la selecci\u00f3n de la terapia en adultos mayores con leucemia mieloide aguda](https://ichgcp.net/es/clinical-trials-registry/NCT03226418)Leucemia mieloide aguda secundaria | Leucemia mieloide aguda relacionada con la terapia | Leucemia mieloide aguda en adultos\n-\nNCT04352673Terminado\n-\nNCT05133622Terminado\n-\n-\nNCT02222922Terminado\n-\nNCT01238523TerminadoFracturas del eje tibial en ni\u00f1os\n-\nNCT02501720Desconocido\n[Comparaci\u00f3n de los resultados de la liberaci\u00f3n de la contractura en flexi\u00f3n posterior a la quemadura con torniquete versus t\u00e9cnica tumescente en ni\u00f1os](https://ichgcp.net/es/clinical-trials-registry/NCT02501720)Contractura en flexi\u00f3n | Quemaduras de manos\n-\nNCT02067533TerminadoReemplazo total de rodilla | Artroplastia total de rodilla (TKA)\n-\nNCT02189707Terminado\n[Efectos de la suplementaci\u00f3n con probi\u00f3ticos sobre el tiempo de tr\u00e1nsito col\u00f3nico y los s\u00edntomas gastrointestinales en adultos con estre\u00f1imiento.](https://ichgcp.net/es/clinical-trials-registry/NCT02189707)Estre\u00f1imiento | Trastorno gastrointestinal\n-\nNCT01066377Desconocido", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT05676320", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT05676320&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT05676320", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Inossia%20AB", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Vertebral%20Compression%20Fracture", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=V-Flex", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=V-Steady", "mailto:malin.nilsson@inossia.com?subject=NCT05676320, SOFTBONE 1512:1, Investigating Bone Cement With or Without Inossia\u2122 Cement Softener for Vertebral Compression Fractures", "mailto:anna.gibernau@clementine.globa?subject=NCT05676320, SOFTBONE 1512:1, Investigating Bone Cement With or Without Inossia\u2122 Cement Softener for Vertebral Compression Fractures", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=V-Flex", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=V-Steady", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Inossia%20AB", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Uppsala%20University", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=EIT%20Health", "https://pubmed.ncbi.nlm.nih.gov/8628042", "https://pubmed.ncbi.nlm.nih.gov/11074683", "https://pubmed.ncbi.nlm.nih.gov/1570766", "https://pubmed.ncbi.nlm.nih.gov/2322694", "https://pubmed.ncbi.nlm.nih.gov/8995096", "https://pubmed.ncbi.nlm.nih.gov/7910248", "https://pubmed.ncbi.nlm.nih.gov/10532877", "https://ichgcp.net/es/clinical-trials-registry/publications/107278-intravertebral-clefts-opacified-during-vertebroplasty-pathogenesis-technical-implications-and", "https://ichgcp.net/es/clinical-trials-registry/publications/107279-evaluation-of-vertebroplasty-with-a-validated-outcome-measure-the-roland-morris-disability", "https://ichgcp.net/es/clinical-trials-registry/publications/107280-vertebroplasty-in-the-inpatient-population", "https://ichgcp.net/es/clinical-trials-registry/publications/107281-vertebroplasty-first-1000-levels-of-a-single-center-evaluation-of-the-outcomes-and-complications", "https://ichgcp.net/es/clinical-trials-registry/publications/107282-pain-response-in-the-first-trimester-after-percutaneous-vertebroplasty-in-patients-with-osteoporotic", "https://pubmed.ncbi.nlm.nih.gov/15931511", "https://pubmed.ncbi.nlm.nih.gov/10529144", "https://ichgcp.net/es/clinical-trials-registry/publications/107283-prospective-measurement-of-function-and-pain-in-patients-with-non-neoplastic-compression-fractures", "https://pubmed.ncbi.nlm.nih.gov/16333624", "https://pubmed.ncbi.nlm.nih.gov/12427813", "https://ichgcp.net/es/clinical-trials-registry/publications/107284-prospective-analysis-of-clinical-outcomes-after-percutaneous-vertebroplasty-for-painful-osteoporotic", "https://ichgcp.net/es/clinical-trials-registry/publications/107285-percutaneous-vertebroplasty-compared-with-optimal-pain-medication-treatment-short-term-clinical", "https://pubmed.ncbi.nlm.nih.gov/2343107", "https://ichgcp.net/es/clinical-trials-registry/publications/107286-new-fractures-after-vertebroplasty-adjacent-fractures-occur-significantly-sooner", "https://pubmed.ncbi.nlm.nih.gov/12511679", "https://pubmed.ncbi.nlm.nih.gov/11136886", "https://pubmed.ncbi.nlm.nih.gov/15597484", "https://pubmed.ncbi.nlm.nih.gov/15590842", "https://ichgcp.net/es/clinical-trials-registry/publications/107287-comparing-pain-reduction-following-kyphoplasty-and-vertebroplasty-for-osteoporotic-vertebral", "https://pubmed.ncbi.nlm.nih.gov/17588820", "https://pubmed.ncbi.nlm.nih.gov/10371229", "https://pubmed.ncbi.nlm.nih.gov/8317445", "https://ichgcp.net/es/clinical-trials-registry/publications/107288-the-relationship-of-health-related-quality-of-life-to-prevalent-and-incident-vertebral-fractures-in", "https://pubmed.ncbi.nlm.nih.gov/9599190", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=osteoporosis", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=kyphoplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=vertebral%20compression%20fracture", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=bone%20cement", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=vertebroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=softener", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Wounds%20and%20Injuries", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Fractures%2C%20Bone", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Fractures%2C%20Compression", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT05912504", "https://ichgcp.net/es/clinical-trials-registry/NCT05519332", "https://ichgcp.net/es/clinical-trials-registry/NCT05337696", "https://ichgcp.net/es/clinical-trials-registry/NCT04835428", "https://ichgcp.net/es/clinical-trials-registry/NCT04821739", "https://ichgcp.net/es/clinical-trials-registry/NCT04795765", "https://ichgcp.net/es/clinical-trials-registry/NCT04064710", "https://ichgcp.net/es/clinical-trials-registry/NCT02387905", "https://ichgcp.net/es/clinical-trials-registry/NCT02285868", "https://ichgcp.net/es/clinical-trials-registry/NCT02657265", "https://ichgcp.net/es/clinical-trials-registry/NCT03226418", "https://ichgcp.net/es/clinical-trials-registry/NCT04352673", "https://ichgcp.net/es/clinical-trials-registry/NCT05133622", "https://ichgcp.net/es/clinical-trials-registry/NCT04782141", "https://ichgcp.net/es/clinical-trials-registry/NCT02222922", "https://ichgcp.net/es/clinical-trials-registry/NCT01238523", "https://ichgcp.net/es/clinical-trials-registry/NCT02501720", "https://ichgcp.net/es/clinical-trials-registry/NCT02067533", "https://ichgcp.net/es/clinical-trials-registry/NCT02189707", "https://ichgcp.net/es/clinical-trials-registry/NCT01066377", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/austria", "https://ichgcp.net/es/cro-list/country/bulgaria", "https://ichgcp.net/es/cro-list/country/congo", "https://ichgcp.net/es/cro-list/country/denmark", "https://ichgcp.net/es/cro-list/country/gambia", "https://ichgcp.net/es/cro-list/country/indonesia", "https://ichgcp.net/es/cro-list/country/kenya", "https://ichgcp.net/es/cro-list/country/new_zealand", "https://ichgcp.net/es/cro-list/country/saint_lucia", "https://ichgcp.net/es/cro-list/country/south_africa", "https://ichgcp.net/es/cro-list/country/suriname", "https://ichgcp.net/es/cro-list/country/ukraine", "https://ichgcp.net/es/cro-list/country/uruguay", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/austria/company/innovacell_biotechnologie", "https://ichgcp.net/es/cro-list/country/austria/company/joanneum_research_health_institute_for_biomedicine_and_health_sciences", "https://ichgcp.net/es/cro-list/country/austria/company/clinical_investigation_support", "https://ichgcp.net/es/cro-list/country/austria/company/zak", "https://ichgcp.net/es/cro-list/country/austria/company/synteract", "https://ichgcp.net/es/cro-list/country/austria/company/bbmri_eric", "https://ichgcp.net/es/cro-list/country/austria/company/psi", "https://ichgcp.net/es/cro-list/country/austria/company/sanaclis", "https://ichgcp.net/es/cro-list/country/austria/company/envigo", "https://ichgcp.net/es/cro-list/country/austria/company/archimedlife", "https://ichgcp.net/es/cro-list/country/austria", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT05676320", "https://ichgcp.net/de/clinical-trials-registry/NCT05676320", "https://ichgcp.net/clinical-trials-registry/NCT05676320", "https://ichgcp.net/es/clinical-trials-registry/NCT05676320", "https://ichgcp.net/fr/clinical-trials-registry/NCT05676320", "https://ichgcp.net/it/clinical-trials-registry/NCT05676320", "https://ichgcp.net/hu/clinical-trials-registry/NCT05676320", "https://ichgcp.net/nl/clinical-trials-registry/NCT05676320", "https://ichgcp.net/no/clinical-trials-registry/NCT05676320", "https://ichgcp.net/pl/clinical-trials-registry/NCT05676320", "https://ichgcp.net/pt/clinical-trials-registry/NCT05676320", "https://ichgcp.net/fi/clinical-trials-registry/NCT05676320", "https://ichgcp.net/sv/clinical-trials-registry/NCT05676320", "https://ichgcp.net/cs/clinical-trials-registry/NCT05676320", "https://ichgcp.net/ru/clinical-trials-registry/NCT05676320", "https://ichgcp.net/ja/clinical-trials-registry/NCT05676320", "https://ichgcp.net/zh/clinical-trials-registry/NCT05676320", "https://ichgcp.net/ko/clinical-trials-registry/NCT05676320", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}